Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Shares Outstanding (Weighted Average) (2016 - 2026)

Amphastar Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 13 years, most recently at $46.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 3.48% year-over-year to $46.7 million; the TTM value through Dec 2025 reached $46.7 million, down 3.48%, while the annual FY2025 figure was $46.7 million, 3.48% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $46.7 million at Amphastar Pharmaceuticals, up from $46.5 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $48.9 million in Q2 2024 and troughed at $46.5 million in Q3 2025.
  • A 5-year average of $48.0 million and a median of $48.2 million in 2022 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 2.47% in 2021 and later fell 4.42% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $47.8 million in 2021, then increased by 1.62% to $48.6 million in 2022, then decreased by 0.59% to $48.3 million in 2023, then increased by 0.34% to $48.4 million in 2024, then dropped by 3.48% to $46.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for AMPH at $46.7 million in Q4 2025, $46.5 million in Q3 2025, and $47.3 million in Q2 2025.